Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
Earnings Data
Report Date
Aug 22, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.24Last Year’s EPS
-1.15Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 8.55%
|Next Earnings Date:Aug 22, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial and operational performance with significant revenue growth, market leadership, and pipeline advancements. Despite challenges in fixed-duration treatments and navigating a complex global environment, the company's strategic initiatives and investments are positioning it well for future growth.Company Guidance
During the call, the company provided detailed guidance and updates across various metrics. For the first quarter of fiscal year 2025, they achieved revenue of $1.1 billion, marking a 49% growth compared to the previous year. The U.S. market saw a 60% increase, with BRUKINSA leading in new patient starts and achieving $563 million in sales, representing a 60% year-over-year growth. The company also achieved GAAP profitability for the first time, with significant improvements in operating profit and cash flow. They anticipate full-year revenue between $4.9 billion and $5.3 billion, maintaining a gross margin in the mid-80 percentile range. Additionally, they highlighted their robust pipeline progress, with over 10 proof-of-concept readouts expected across their solid tumor pipeline in 2025, and emphasized the strategic investments made to ensure supply chain resiliency, including an $800 million investment in a New Jersey manufacturing facility. The company also announced their redomiciling to Switzerland, reflecting their evolution into a globally diversified oncology leader.Record-Breaking Revenue Growth
Global sales reached $1.1 billion in Q1 2025, marking a 49% increase from Q1 2024. The U.S. market alone grew by 60%, driven by strong demand for BRUKINSA.
BRUKINSA's Market Leadership
BRUKINSA became the market leader by revenue in the U.S. BTK market, with Q1 2025 sales reaching $563 million, a 60% growth compared to the previous year. It surpassed competitors in new patient starts for CLL.
GAAP Profitability Achieved
For the first time, the company achieved GAAP profitability, with net income showing significant improvement from the previous year.
Robust Pipeline Progress
The company is advancing a strong pipeline, including the BTK CDAC and sonro, with multiple Phase III trials initiated and more than 10 proof-of-concept readouts expected in 2025.
Global Expansion and Growth
Significant sales growth was seen in Europe (75% increase) and the rest of the world (146% increase), driven by new launches and market expansion.
ONC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ONC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $241.75 | $232.25 | -3.93% |
Mar 27, 2025 | $250.92 | $262.60 | +4.65% |
Nov 12, 2024 | $205.04 | $193.64 | -5.56% |
Aug 27, 2024 | $199.22 | $202.17 | +1.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BeiGene (ONC) report earnings?
BeiGene (ONC) is schdueled to report earning on Aug 22, 2025, TBA Not Confirmed.
What is BeiGene (ONC) earnings time?
BeiGene (ONC) earnings time is at Aug 22, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ONC EPS forecast?
ONC EPS forecast for the fiscal quarter 2025 (Q2) is 0.24.